• Zelira successfully completed a Phase 1 dose escalation study to assess the safety of itscannabis formulation (ZTL-103) in seven chronic pain patients already using high doses ofopioids.
• ZTL-103 treatment was well tolerated with no serious adverse events
Primary Endpoints Achieved:
ZTL-103 is safe
• No serious adverse events reported
• Non-serious adverse events were mild and transient
• Maximal dose was generally well tolerated
Secondary Endpoints Achieved:
•Pharmacokinetic Analysis:
• ZTL-103 Treatment Improved Subjective Measures of Pain
• ZTL-103 Treatment Improved Subjective Measures of Anxiety, Stress and Depression
Not expecting much impact to the SP, however, next target is insomnia & HOPE products sales and that's where I believe the SP will go to mid-late teens easily.. 3-6 months I HOPE!
We should see some smart money coming in between now and then..
GLTAH & please DYOR!
